Healthcare Pharmaceuticals Limited (HPL) is pleased to present its Vaccine Manufacturing Unit, a state-of-the-art facility established in December 2012 to meet the growing global demand for high-quality human vaccines. The facility has been designed with precision, ensuring safety, efficiency, and adherence to the strictest quality standards. Spanning three levels, it also includes a dedicated utility building to support all operational requirements. Each area within the facility has been carefully arranged to optimize production workflows while maintaining strict safety and quality protocols.

The facility’s layout is structured to maximize efficiency at every stage of vaccine production. The ground floor, or Level 1, is dedicated to the production of vaccine products. This level features a specialized material loading and unloading area, along with an advanced HVAC system to maintain the necessary temperature and air quality controls for sensitive vaccine production. Additionally, it is equipped with a comprehensive water distribution system and firefighting equipment to ensure the safety of both personnel and the integrity of the products during manufacturing.

HPL’s Vaccine Manufacturing Unit operates in full compliance with Good Manufacturing Practices (GMP), certified by the Directorate General of Drug Administration (DGDA), Ministry of Health & Family Welfare, Government of Bangladesh. Furthermore, HPL is in the process of obtaining WHO certification, which underscores its commitment to meeting the highest international standards for vaccine production.

The unit specializes in the production of human vaccines, utilizing the latest advancements in vaccine manufacturing technology. The HVAC system has been meticulously designed to ensure consistent environmental conditions by maintaining separate zones within the facility, thus preventing cross-contamination and guaranteeing vaccine safety and efficacy throughout the production process.

HPL’s Quality Management System (QMS) at the Vaccine Manufacturing Unit adheres to global regulatory guidelines, such as EudraLex Volume 4 and 21 CFR 210 & 211. The QMS includes critical components such as Deviation Management, Change Control, Quality Risk Management, and Corrective and Preventive Actions (CAPA). These processes are carefully monitored using digital platforms, including eQMS, DMS, and LMS, to ensure continuous product quality and regulatory compliance. Finished products are released through SAP for enhanced traceability and accountability, ensuring every step of production is fully documented.

Supporting the Vaccine Manufacturing Unit is a dedicated Research and Development (R&D) facility and a specialized Quality Control (QC) laboratory that focuses exclusively on vaccine products. These facilities play a key role in HPL’s ongoing commitment to innovation and improvement in vaccine production, helping to ensure that the company remains at the forefront of the industry.

Safety is paramount at HPL, and the Vaccine Manufacturing Unit is equipped with advanced fire detection and suppression systems at every level of the facility. Dedicated water treatment systems are in place to deliver high-purity water, essential for vaccine production, while reinforcing HPL’s commitment to environmental sustainability and product safety.

With cutting-edge technology, a skilled workforce, and adherence to the highest international regulatory standards, HPL’s Vaccine Manufacturing Unit is positioned as a leader in human vaccine production. The unit is dedicated to delivering safe and effective vaccines that meet global health needs and quality standards.